COsegregation of VARiants in Panel of Genes (COVAR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01689584 |
|
Recruitment Status :
Recruiting
First Posted : September 21, 2012
Last Update Posted : August 3, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Gene Mutation-Related Cancer Genetic Predisposition | Genetic: salivary kit | Not Applicable |
Originally, the COVAR study was designed to explore Variants of unknown biological significance (VUS) in BRCA1 (BReast Cancer 1) and BRCA2 (BReast Cancer 2) genes, which are the two major genes identified in hereditary breast and/or ovarian cancers. Since then the study has evolved, in parallel with the evolution of diagnosis, first introducing the PALB2 (Partner and localizer of BRCA2) gene explored in diagnosis since 2015 and now opening the study to all the genes of the panels performed in diagnosis in families with a genetic predisposition syndrome to cancers.
The French UMD (Universal Mutation Database)-BRCA1/2, accredited by the French National Cancer Institute, collects anonymous results of genetic tests performed by authorized French laboratories since 1995, giving a real-time vision of families carrying the same VUS. In september 2011, the French UMD-BRCA1/2 database comprised 706 different variants in 1,300 BRCA1 families and 1,089 different variants in 2,101 BRCA2 families. In April 2021, this database contained 1,651 different VSU for BRCA1, 3,015 different VUS for BRCA2, 471 different VUS for PALB2, 68 for RAD51C and 66 for RAD51D.
Since 2017, new genes have been explored in the diagnostic setting as they have been reported as predisposing factors for cancers. This list is constantly evolving (Moretta et al., 2018; Dhooge et al., 2020). Data collection for these genes is ongoing and a new database (FrOG) gathering all VUS and mutations identified in the French oncogenetic network has been set up. We have set up a consortium agreement at the end of 2020. This database gathers to date 12 genes and 11,912 different variants in more than 40,000 French families.
One of the key measurable parameters for classification of VUS as causal mutations is their co-segregation with the disease. The average size of French families is relatively small, the information of variant co-segregation limited to one family would not be significant. However, the compilation of co-segregation results obtained from several families will allow to obtain more precise and complete estimations of the probability of causality of a given variant.
The objective of the COVAR study (COsegregation VARiants) is to organize co-segregation studies of the VUS of the database UMD-BRCA1/2, in order to determine the causal or non-causal nature of these variants. To organize the variants by their clinical relevance, a grid with 5 classes has been used: 1=neutral, 2=likely neutral, 3=VUS, 4=likely causal, 5=causal. The VUS of classes 3 and 4 will be candidates to co-segregation studies because they cannot be used for the genetic counseling.
In the selected families the index case will invite the family members (affected and unaffected) to provide a sample of salivary fluid to test the presence of the VUS. The probability that a VUS is causal will be calculated from the cosegregation data using a Bayesian model. The results will be integrated in the multifactorial model described by D. Goldgar, model integrating different parameters as amino acid conservation, structural impact of the variant, co-occurrence with a pathogenic mutation, family history and tumor characteristics.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 3500 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling |
| Actual Study Start Date : | April 2012 |
| Estimated Primary Completion Date : | December 2022 |
| Estimated Study Completion Date : | December 2027 |
| Arm | Intervention/treatment |
|---|---|
| Covar |
Genetic: salivary kit
The saliva samples will be made of selected related (DNA). |
- Perform the co-segregation analysis of the selected VUS in the families in order to classify the maximum of variants in terms of their probability to be pathogenic [ Time Frame: up to 15 years ]
- • Propose a standardized method to classify VUS that can be integrated into the already existing classification established in the UMD-BRCA1/2 database, with the main focus on variants of class 4 (probably causal) and class 3 (unknown significance). [ Time Frame: up to 15 years ]
- • Maximize the number of VUS (both pathogenic and neutral) having associated recommendations for clinical management of at-risk relatives that can be used to guide genetic counselling. [ Time Frame: up to 15 years ]
- Assess the penetrance of several class 3 and 4 VUS probably associated with moderate cancer risk, using collected phenotype/genotype data on extended pedigrees. [ Time Frame: up to 15 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Index cases:
- A person carrying a gene variant class 3 or 4, present and selected in the families of national database of genetic group and cancer (GGC Unicancer) which identifies the variations of all genes from the panel of genes of all French laboratories.
- Age ≥ 18 years.
- Signed written inform consent "index case"
Related parties:
- Any relative of an index case with cancer
- Any relative without cancer related to an index case, retained by investigators, based on family structure and degree of related compared to the index case
- Age ≥ 18 years
- Information and signature of the informed consent "selected relatives"
Exclusion Criteria:
- Minors
- Persons deprived of liberty or under guardianship (including curators).
- Absence of signed written inform consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01689584
| Contact: Sandrine CAPUTO, PhD | 33172389367 | sandrine.caputo@curie.fr | |
| Contact: Isabelle TURBIEZ, Project Manager | 33147111659 | isabelle.turbiez@curie.fr |
Show 57 study locations
| Study Chair: | Dominique STOPPA-LYONNET, PU-PH | Institut Curie | |
| Study Director: | Sandrine CAPUTO, PhD | Institut Curie |
| Responsible Party: | Institut Curie |
| ClinicalTrials.gov Identifier: | NCT01689584 |
| Other Study ID Numbers: |
IC 2011-11 |
| First Posted: | September 21, 2012 Key Record Dates |
| Last Update Posted: | August 3, 2021 |
| Last Verified: | August 2021 |
|
BRCA1 BRCA2 VUS co-segregation |
genetic counseling PALB2 panel of genes |
|
Disease Susceptibility Genetic Predisposition to Disease Disease Attributes Pathologic Processes |